Hematologic Oncology

This video explores the current treatment landscape for lower-risk MDS patients, including the various agents and sequencing strategies employed to best optimize outcomes.

As we learn more about the biology of AML, it appears that 7+3 only rarely clears residual leukemic clones in patients with higher-risk disease. New therapies are needed that can target and eradicate resistant subclones early in the disease course.

Adding rituximab to an escalated regimen of BEACOPP did not improve progression-free survival in patients with advanced-stage Hodgkin lymphoma.

Researchers at the Mayo Clinic are reporting that they have identified a new therapy that shrinks tumors in patients with multiple myeloma.

The final, long-term analysis of the landmark IRIS study showed that imatinib’s efficacy persists over time in patients with CML, and no unacceptable late toxic or cumulative effects were observed.

Establishing a multidisciplinary oral chemotherapy clinic in a community hospital is feasible and could help reduce emergency department visits, recognize adverse events earlier, and improve staff and patient satisfaction.

We spoke with Dr. Anas Younes about the molecular characteristics of diffuse large B-cell lymphoma.

The FDA has expanded the approval of lenalidomide to include its use as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.

In this interview we discuss the latest therapy developments in the treatment of multiple myeloma.

The emergence of ibrutinib-resistant chronic lymphocytic leukemia (CLL) can be detected prior to clinical relapse, according to an analysis of patients from four ibrutinib trials.

A handful of novel antibody-based therapies may soon emerge for the treatment of acute myeloid leukemia, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies.

Cessation of second-generation TKIs yielded good treatment-free remission rates in patients with chronic myeloid leukemia who had sustained deep molecular responses.

Significant progress has been made in the treatment of chronic lymphocytic leukemia with the addition of options such as the tyrosine kinase inhibitor ibrutinib, the monoclonal antibody obinutuzumab, and the BCL2 inhibitor venetoclax.

Smoking is linked to mortality and to disease progression among patients with chronic myeloid leukemia.

Three courses of clofarabine combined with cytarabine may improve relapse-free survival in patients with acute myeloid leukemia in first remission.

In this interview we discuss clinical developments in essential thrombocythemia, polycythemia vera, and myelofibrosis, as well as the latest treatment options.

New treatment options are now available for light-chain amyloidosis, with additional ones on the way, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies.

Adolescents and young adults with leukemia experienced inferior outcomes compared with children, especially if they were treated outside of a specialized cancer center.

Patients with chronic lymphocytic leukemia who discontinue treatment with ibrutinib due to disease progression or transformation had significantly worse survival compared with patients who discontinued therapy because of intolerance.

A 60-year-old man with a history of coronary artery disease and JAK2 V617F–positive polycythemia vera presented to our bone marrow transplantation clinic with progressive fatigue, splenomegaly, and cytopenias.

This article reviews newly approved drugs for hematologic malignancies: their indications, mechanisms of action, accompanying pivotal trial data, pertinent toxicities, use in special populations, and appropriate clinical context.

Genetic profiling combined with clinical factors may help guide clinicians on how to better manage patients with myelodysplastic syndrome.

There was no association between conventional response outcomes, such as complete response or very good partial response, and survival in patients with newly diagnosed multiple myeloma.

Despite significant toxicities, idelalisib improved time to progression for patients with treatment-resistant chronic lymphocytic leukemia.